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825Noninvasive Imaging of Cardiovascular Injury
Related to the Treatment of CancerABSTRACTThe introduction of multiple treatments for cancer, including chemotherapeutic agents and radiation therapy, has
signiﬁcantly reduced cancer-related morbidity and mortality. However, these therapies can promote a variety of toxic-
ities, among the most severe being the ones involving the cardiovascular system. Currently, for many surviving cancer
patients, cardiovascular (CV) events represent the primary cause of morbidity and mortality. Recent data suggest that CV
injury occurs early during cancer treatment, creating a substrate for subsequent cardiovascular events. Researchers have
investigated the utility of noninvasive imaging strategies to detect the presence of CV injury during and after completion
of cancer treatment because it starts early during cancer therapy, often preceding the development of chemotherapy or
cancer therapeutics related cardiac dysfunction. In this State-of-the-Art Paper, we review the utility of current clinical
and investigative CV noninvasive modalities for the identiﬁcation and characterization of cancer treatment-related CV
toxicity. (J Am Coll Cardiol Img 2014;7:824–38) © 2014 by the American College of Cardiology Foundation.A dvancements in the treatment of canceroccurring over the past 3 decades have re-sulted in decreased cancer-related morbidity
and mortality, and increased long-term survivorship.
Today, data from billing codes related to cancer pa-
tients indicate that cardiovascular (CV) disease
(CVD) is the leading cause of death among breast
cancer survivors, replacing recurrent cancer or devel-
opment of a new cancer (1). In childhood cancer sur-
vivors (2,3), the risk of CV death is now higher than
the actual risk of tumor recurrence (with a reported
7-fold increase in cardiac mortality rate relative to
siblings without cancer).
In this paper, we review the cancer therapies and
their associated CV events, existing noninvasive im-
aging study results highlighting methods to detect
early evidence of CV injury upon receipt of treatment
for cancer, and emerging noninvasive imaging tech-
nologies that may further enhance the detection
of CV injury. Results of several studies raise the
possibility that noninvasive imaging may be useful
for identifying CV injury after receipt of cancer
treatment.
CARDIOVASCULAR INJURY FROM
CANCER TREATMENT
The type and duration of cancer treatment still plays
an important role in determining CV injury or
toxicity. Cardiovascular toxicity can be caused by: 1)
direct injury to or death of cardiac myocytes; 2)
stimulation of myocardial ﬁbrosis; 3) provocation
of stress induced myocardial ischemia via endo-
thelial dysfunction; 4) vascular injury; 5) myocardial
and/or pericardial inﬂammation; 6) arrhythmogenicor conduction abnormalities; 7) autonomic dysfunc-
tion; 8) valvular disease; or 9) exacerbation of known
CV risk factors (e.g., hypertension, accelerated
atherosclerosis, or Raynaud’s syndrome, etc.) (4,5). In
addition to traditional cardiotoxic agents, such as
anthracyclines or radiation-related heart disease,
newer therapies including tyrosine kinase inhibitors
(6–11) and even therapies that are not necessarily
classiﬁed as “chemotherapy” may also promote CV
disease or events. For example, the administration of
hormone deprivation therapies, which have dramat-
ically reduced cancer recurrence and improved sur-
vival in women with breast cancer or men with
prostate cancer, are now increasingly associated with
CV events (12–16). Online Table 1 in the Online Ap-
pendix presents a summary of the types of cardiac
injuries, the agents that commonly cause these in-
juries, and noninvasive investigations to determine
the extent of these injuries.
CURRENT CLINICAL NONINVASIVE IMAGING
STRATEGIES FOR SCREENING CANCER
TREATMENT-RELATED CARDIOTOXICITY
A literature review from the American Society of
Clinical Oncology has recently noted that there are no
available systematic evaluations published regarding
the role of routine noninvasive testing for cardiac
dysfunction in patients treated for cancer. Moreover,
the effectiveness of screening techniques for detect-
ing subclinical CV injury in asymptomatic survivors
of cancer is not established. Yet, there are recent
research initiatives suggesting the possible utility of
noninvasive imaging technologies for identifying
subclinical CV injury in those receiving treatment for
ABBR EV I A T I ON S
AND ACRONYMS
2D = 2-dimensional
3D = 3-dimensional
CMR = cardiovascular magnetic
resonance
CV = cardiovascular
CVD = cardiovascular disease
ERNA = equilibrium
radionuclide angiography
ERNV = equilibrium
radionuclide ventriculography
FDG = 18F-ﬂuorodeoxyglucose
GLS = global longitudinal
strain
IVRT = isovolumic relaxation
time
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular ejection
fraction
LVMi = left ventricular mass
index
MIBG =
metaiodobenzylguanidine
MRS = magnetic resonance
spectroscopy
PFR = peak ﬁlling rate
SPECT = single-photon
emission computed
tomography
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826and surviving cancer. In the following sec-
tions, we provide an overview of the data
accumulated to date that address the utility of
noninvasive imaging strategies for assessing
cancer therapy related to CV disease.
NUCLEAR MEDICINE IMAGING. The ﬁrst
studies of cancer therapy-related cardiac
toxicity relied on equilibrium radionuclide
angiography (ERNA) to measure left ventric-
ular (LV) function through determination of
LV ejection fraction (LVEF). Established in
the 1970s, reductions in LVEF identiﬁed
those with anthracycline-related cardiotox-
icity; in the single largest study using serial
ERNA, 19% of patients who dropped their
LVEF by >10% from baseline, or to a
value <50% went on to develop heart failure
(17). Today, ERNA is used to identify LV
dysfunction from other cardiotoxic agents
(17,18).
In addition to resting measures of LVEF,
investigators have also assessed the utility of
ERNA stress-induced changes in LVEF as
markers of early anthracycline induced car-
diomyopathy. McKillop et al. (19) found
that the sensitivity for detecting patients
that may develop heart failure increased
from 58% to 100%, but this occurred with a
concomitant decrease in speciﬁcity from
75% to 41%. Thus, to date, stress nuclearassessments of LVEF to identify cardiac injury
after receipt of anthracycline are not widely
performed.
In addition to systolic dysfunction, LV diastolic
function is often assessed with radioisotope-based
techniques. Count–time curves, the peak ﬁlling rate
(PFR), the PFR normalized to stroke volume, and
time-to-peak ﬁlling rate detected with planar equi-
librium radionuclide ventriculography (ERNV) are
associated with anthracycline-induced diastolic
dysfunction (20,21). Reductions in these ERNV mea-
sures of LV diastolic function correlate with the
simultaneous decreases in LVEF, suggesting that
anthracyclines impair both systolic and diastolic
function (21). Moreover, a recent study by Cochet
et al. (22) demonstrates that baseline prolongation of
time-to-peak ﬁlling rate (which reﬂects impairment of
diastolic function before treatment) is an indepen-
dent predictor for trastuzumab-mediated cardiotox-
icity after adjuvant anthracycline therapy in breast
cancer.
It is important to recognize that although ERNA
is widely available for identifying LV dysfunctionassociated with chemotherapy-related cardiotoxicity
(17,20,23,24), there are limitations to the procedure.
First, the procedure exposes patients to an ionizing
radiation dose (estimated at 7.8 mSv per examina-
tion). This is problematic for childhood cancer pa-
tients or those who receive repeated exposures by
surveillance protocol guidelines. Second, the proce-
dure produces little information regarding other car-
diac parameters such as those related to valvular
structure or the pericardial space. Finally, the tech-
nique is not well suited for detecting small changes in
LVEF or direct measures of myocardial injury that
may provide important evidence of early injury that
predispose one to future CV events.
In patients with heart failure, the single-photon
emission computed tomography (SPECT) and posi-
tron emission tomography (PET) techniques using
radiolabeled neurotransmitters and receptor ligands
have been used to evaluate pre-synaptic reuptake,
neurotransmitter storage, and also activity of post-
synaptic receptors (25–27). Metaiodobenzylguanidine
(MIBG) is a quanethidine analog that shares type I
adrenergic neuroreceptor uptake storage and release
mechanisms throughout the body with norepineph-
rine (25–27). After being labeled with 123I, uptake of
regional 123I-MIBG reﬂects neuronal integrity, and its
release reﬂects adrenergic function (25–27). Calcula-
tion of the heart-to-mediastinum count ratio of
123I-MIBG uptake and delay in the 4-h post-injection
washout rates have been observed in patients with
heart failure or those receiving anthracycline-based
chemotherapy. Also, a decrease in the heart-to-
mediastinum count ratio correlated with a higher
cumulative dose of anthracycline (27–29). Decreases
of MIBG uptake may be seen up to 10 years after
development of heart failure in patients with a his-
tory of severe anthracycline-induced cardiomyopa-
thy, regardless of recovery of LV function. These
ﬁndings suggest myocardial cell injury and adren-
ergic dysfunction from destruction of adrenergic
nerve tissue and functional alteration or adrenergic
nerves by cytotoxic effect of itself, as in animal or
human models, may persist for years after the initial
exposure to anthracyclines (30,31).
ECHOCARDIOGRAPHY. Its wide availability and
absence of nonionizing radiation render echocardi-
ography a very attractive imaging option for assessing
patients with cardiac abnormalities during or after
cancer treatment (32–37). In addition to evaluating LV
structure, echocardiography provides information on
both systolic function (LVEF and fractional short-
ening in the pediatric population), and diastolic
function (E/A ratio, E/e0, e0, isovolumic relaxation
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Also, recent techniques have become available to
measure myocardial deformation, including LV
strain, strain rate, or twist and torsion that may pro-
vide new understanding regarding the early stages of
the pathophysiology of cardiac dysfunction upon
receipt of cancer treatment (37,45–50). Moreover,
echocardiography provides additional informa-
tion about valvular function and pericardial ﬂuid/
physiology that might occur after cancer treatment
(32,51,52).
From a standard 2-dimensional (2D) echocardio-
gram, LVEF can be estimated visually, or quantiﬁed
by M-mode (the fractional shortening method),
single or biplane area-length methods, or the modi-
ﬁed Simpson summation of disks technique as per
American Society of Echocardiography chamber
quantiﬁcation guidelines (53). In general, CV medicine
consultations should be considered for those patients
experiencing reductions in LVEF of $5% to <55% with
symptoms of heart failure, or an asymptomatic
reduction in the LVEF of $10% (54,55). It is important
to note, however, that although 2D echocardiography
can identify relatively large drops in LVEF (e.g.,
from 60% to 40%), smaller changes such as from 54%
to 48% are more difﬁcult to obtain with a high degree
of certainty (17,23,56).
To address this limitation, 3-dimensional (3D)
methods are now available to improve the detec-
tion of small changes in LVEF (40,42). Recently,
Thavendiranathan et al. (57) demonstrated that 3D
echocardiography was more reproducible and had
lower interobserver variability LVEF and volume
measurements. This ﬁnding correlated well with a
previous study by Walker et al. (35) that found the
technique to be more accurate when compared with
2D, and not inferior when compared with multigated
acquisition scanning and cardiac magnetic resonance.
To date, however, researchers have not accomplished
the utilization of 3D echocardiographic strategies in
measuring LVEF on a large scale in community hos-
pitals or clinically in large numbers of patients treated
for cancer for the purpose of detecting CV injury.
Some studies have shown that LV diastolic prop-
erties, such as a decrease in the E/A ratio, or prolon-
gation of IVRT or deceleration time of early diastolic
ﬁlling can predict doxorubicin-induced LV systolic
dysfunction (58,59). However, other studies have not
observed a relationship between changes in diastolic
measures and long-term changes in LVEF (60,61). In
fact, increases in the E/A ratio and shortening of IVRT
occurring 1 h after administration of the ﬁrst dose of
doxorubicin can return to pre-chemotherapy levels
within 3 weeks (60,61). Given the transient nature ofthese diastolic ﬁndings, they have not been widely
utilized to direct cardioprotective strategies to pre-
vent chemotherapy-related cardiotoxicity.
One newer measure that may be helpful to identify
cardiac injury includes the assessment of global lon-
gitudinal strain (GLS) (Fig. 1) (39,41). In general, lon-
gitudinal LV mechanics are the most vulnerable and
highly reproducible component of LV mechanics that
can be assessed with well-performed transthoracic
echocardiography (39–41). Stoodley et al. (50)
demonstrated that anthracycline chemotherapy can
reduce global and regional longitudinal and radial
strain by more than 10% as early as 1 week after
receipt of treatment. This corresponds well with re-
sults by Sawaya et al. (37) in which reduced global
longitudinal and radial strain after 3 months of cancer
treatment with an anthracycline and trastuzumab
predicted the later development of a reduction of
LVEF 6 months after initiation of these therapies. In
this same study, reductions in longitudinal strain of
>10% from baseline predicted future declines in LVEF
with a sensitivity of 78% and speciﬁcity of 79%, and a
negative predictive value of 93%. Abnormalities of
global measures of longitudinal strain evaluated in
combination with determinations of ultrasensitive
troponin I measured at the completion of treatment
may prognosticate subsequent development of LV
dysfunction 12 and 15 months after completion of
chemotherapy treatment (p ¼ 0.0003 and p ¼ 0.04,
respectively) (62,63). In a recent systematic review,
a 10% to 15% early reduction in GLS by speckle
tracking echocardiography during therapy appears
to be the most useful parameter for the prediction
of cardiotoxicity deﬁned as a drop in LVEF or heart
failure (64).
Myocardial twist, untwist, and torsion of the LV
apex have been studied with transthoracic echocar-
diography. Myoﬁlament disorganization and car-
diomyocyte necrosis impact the passive and restoring
forces of the ventricle in in vitro animal model studies
(43,65). To this end, Motoki et al. (48) identiﬁed
deterioration in LV apical and torsion, twisting rates,
and untwisting rates 1 month after chemotherapy that
correlated with prolongation of IVRT 3 months after
chemotherapy. However, this ﬁnding did not forecast
future reductions in LVEF or CV events. Cheung et al.
(45) demonstrated that 1 year after treating children
with acute lymphoblastic leukemia, LV apical torsion
and twisting and untwisting velocities were reduced.
Future studies are required to determine the prog-
nostic utility of echocardiographic measures of twist
and torsion in those treated for cancer.
The role of microbubble contrast in assessing car-
diac function after treatment for cancer is not well
FIGURE 1 2D Speckle-Tracking Echocardiogram-Based Strain in a Patient With Invasive Ductal Carcinoma
A patient with invasive ductal carcinoma (estrogen receptor negative, progesterone receptor negative, human epidermal growth factor receptor
2/neu positive), treated with the TCH regimen (docetaxel, carboplatinum, and trastuzumab), had a baseline ejection fraction (EF) of 65%. The
EF after 3 months of therapy was 58%. (A and B) utilize color to illustrate the global longitudinal strain (GLS) and regional strain values
obtained at baseline (pre-chemotherapy) and 3 months after the initiation of trastuzumab-based regimen. The septal and anteroseptal seg-
ments exhibit abnormal regional strain after treatment. (Courtesy of Dr. Juan Carlos Plana, MD, FACC, Co-Director Cardio-Oncology Center,
Cleveland Clinic, Cleveland, Ohio). 2D ¼ 2-dimensional; AVC ¼ aortic valve closure.
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to its overall utility. In those patients with poor
LV endocardial visualization, the American Society
of Echocardiography suggests the intravenous ad-
ministration of microbubble contrast may improve
assessment of LV wall motion and LVEF post-cancer
treatment, especially in those undergoing mastec-
tomy or breast implants (66). However, recently,
Thavendiranathan et al. (57) demonstrated that in
breast cancer patients post-chemotherapy with stable
measures of GLS, noncontrast 3D assessments of
LVEF exhibited lower temporal variability in com-
parison with contrast-based methods.
CARDIOVASCULAR COMPUTED TOMOGRAPHY. The
use of cardiovascular computed tomography to assess
the CV system after treatment for cancer and to
forecast future CV events has not been well studied.
This technology may be useful in 2 respects: ﬁrst, for
evaluating the pericardium of patients that received
radiation or surgical treatments to identify abnormal
thickening and calciﬁcation of the pericardium,
and second, to measure coronary artery calcium ordirectly visualize the coronary arteries (67). Although
coronary artery calcium scores are elevated when
mediastinal radiation is administered at doses >20 Gy
(68,69), and anthracycline chemotherapy has been
associated with accelerated atherosclerosis (69–72), in
the absence of symptomatic coronary artery disease,
there is currently insufﬁcient data to recommend the
routine use of coronary CT angiography or calcium
scoring in patients who underwent high-dose radia-
tion therapy. In addition, the presence of coronary
artery calciﬁcation before treatment for cancer has
not been shown to predict future CV risk upon receipt
of chemotherapy, tyrosine kinase inhibitors, or radi-
ation therapy. For these reasons, cardiovascular
computed tomography has not been widely used to
screen for adverse subclinical CV disease after cancer
treatment or predict CV risk pre-cancer treatment.
Whether existing planning or surveillance images
acquired as components of clinical exams used to
stage cancer could be used for these purposes re-
quires further study (68–73). At present, information
related to the CV system is often not reported on
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lance studies.
CARDIOVASCULAR MAGNETIC RESONANCE.
Cardiovascular magnetic resonance (CMR) is a versa-
tile imaging modality in that with a single examina-
tion, one can gather information pertaining to cardiac
and vascular anatomy, tissue characteristics (pres-
ence of ﬁbrosis, inﬂammation, injury, etc.), left and
right ventricular systolic or diastolic function, blood
ﬂow, and myocardial perfusion or metabolism
(35,42,57,74). These assessments are accurate and
reproducible, exhibit high spatial and temporal reso-
lution, and do not expose individuals to ionizing
electromagnetic radiation. For this reason, the
American College of Cardiology/American Heart As-
sociation recognizes CMR as a method to identify
CV dysfunction after treatment for cancer and has
incorporated it across research studies to deﬁne
the pathophysiology of cancer treatment-related CV
toxicity (75). In addition, CMR can detect myocardial
masses associated with metastases, or evaluate the
pericardium and pericardial space, and when neces-
sary, assess valuable function (76).
Researchers and clinicians have used LV myocar-
dial mass, volume, and systolic and diastolic function
assessments measured from cine white blood imaging
sequences to identify evidence of cardiomyopathy
among adult cancer survivors (77). Neilan et al. (78)
demonstrated an inverse correlation between
anthracycline dosage and CMR-derived LV mass in-
dex (LVMi) (r ¼ 0.67; p < 0.001), and an association of
LVMi with major adverse CV events (hazard ratio:
0.89, p < 0.001). These results indicated a sensitivity
of 100% and speciﬁcity of 85% to predict major
adverse CV events if the LVMi was #57 g/m2 after
treatment with anthracycline chemotherapy.
In addition to reductions in LV mass, an increase in
LV cavity end-systolic volume is associated with the
subsequent reduction in LVEF after treatment with
trastuzumab or anthracycline-based chemotherapy
(35,79,80). Drafts et al. (80) followed 51 subjects
treated with anthracycline-based chemotherapy and
identiﬁed early increases in LV end-systolic volume
commensurate with deteriorations in LVEF, myocar-
dial strain, and ability to perform activities of daily
living. In addition, these cardiac and of quality-of-life
metrics occurred commensurate with increases in
serum troponin levels (35,76,77).
A unique feature of CMR is the ability to charac-
terize myocardial tissue by the use of relaxation times
(T1, T2, and T2*) in order to identify myocardial injury
and ﬁbrosis. Speciﬁcally, T2-weighted images are
sensitive to regional or global increases of myocardialwater content that accumulates in the setting of
myocellular or microvascular injury or inﬂammation
(81). A previous small study by Oberholzer et al. (82)
identiﬁed myocardial edema from a T2-weighted
study post-anthracycline treatment. Further research
is ongoing regarding the utility of T2 mapping tech-
niques of the LV myocardium in patients receiving
treatment for cancer (83).
In addition to assessing myocardial T2 relaxation,
properties related to T1 relaxation may also provide
insight regarding myocardial injury and ﬁbrosis
related to the administration of chemotherapy. In
rodent models, Lightfoot et al. (84) demonstrated
that an increase in gadolinium-enhanced signal in-
tensity on T1-weighted images after treatment with
doxorubicin was associated with histopathological
evidence of intracellular vacuolization (consistent
with doxorubicin-induced cardiotoxicity) and fore-
casted a subsequent reduction in LVEF. In a clinical
study by Wassmuth et al. (85), an increase of gado-
linium signal intensity on post-contrast T1-weighted
images within 3 days of the receipt of anthracycline
infusions predicted a signiﬁcant decline in LVEF at 28
days (p < 0.05). Tham et al. (86) demonstrated that
changes in myocardial T1 values occurred in children
post-exposure to anthracycline without correlation to
anthracycline levels. Long-term clinical outcome
studies are needed to determine whether T1/T2
mapping ﬁndings are associated the adverse clinical
CV outcomes in patients treated for cancer.
Myocardial ﬁbrosis by late gadolinium enhance-
ment (LGE) is associated with an adverse CV prognosis
in patients with coronary artery disease, hypertrophic
cardiomyopathy, or inﬁltrative diseases such as
amyloidosis and sarcoidosis (86). For those treated for
cancer, data pertaining to the association of LGE with
cancer treatment are mostly anecdotal or observa-
tional, and somewhat conﬂicting in regard to reported
results. In a chemotoxic cardiomyopathy study by
Catalano et al. (87), mid-myocardial LGE is shown in
the mid-basal septum and anterior, basal antero-
lateral, and mid-inferior walls after treatment with
anthracycline/cyclophosphamide, and a study by Fal-
lah-Rad et al. (79,88) demonstrates mid-myocardial
LGE patterns in the lateral wall after treatment with
trastuzumab for 12 months. By contrast, Neilan et al.
(78) determined that LGE is an infrequent ﬁnding
occurring in only 6% (5 cases/91 cases) of patients
treated with anthracycline-base chemotherapy de-
spite a reduced LVEF. In addition, a study by Bittner
et al. (89) demonstrated that LGE occurs only in 8%
(2 cases/25 cases) of patients treated with adjuvant
trastuzumab without any change in systolic function
or routine diastolic ﬁlling parameters.
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malities pertaining to the heart, treatment for cancer
with hormonal deprivation agents, tyrosine kinase
inhibitors, or anthracyclines may impact the vascu-
lature and thereby contribute to other CV events
such as stroke and myocardial infarction. Recently,
Chaosuwannakit et al. (90) demonstrated that prox-
imal aortic wall stiffness increased 3 months after
receipt of anthracycline-based chemotherapy after
controlling for factors such as age, sex, diabetes,
hyperlipidemia, and hypertension. The increase in
stiffening occurred soon after administration of
chemotherapy, was not dose dependent, and was
equivalent to that associated with aging the CV sys-
tem by 10 to 20 years (Fig. 2). In other patient pop-
ulations, such as those with diabetes, hypertension,
renal failure, and advanced age, abnormal increases
in proximal aortic stiffness have been associated
with LV hypertrophy, exercise intolerance, and
future CV events (91).FIGURE 2 PWV Assessments of Aortic Stiffness After Cancer Treatm
Sagittal magnitude image of the thoracic aorta was used to select the a
aortic ﬂow (solid white line). The distance between ascending and desc
aortic lumen (red line). The 2 velocity–time curves are shown across the
velocity–time curves for the ascending and descending thoracic aortas. Tr
time difference of the velocity–time curve at 2 different regions (green
velocity curves was used to estimate the time delay. Pulsed wave velocity
and descending thoracic aortas by the transit time of the ﬂow wave. Ca
by the measurement of the PWV between control participants without c
baseline and after 4 months of treatment. As shown, the PWV increased
of the increase in PWV is equivalent in other populations to an aortic-sti
from Chaosuwannakit et al. (90).It is important to note that although CMR is accu-
rate and reproducible, it does not expose one to
ionizing radiation, and assesses multiple aspects of
the CV system in a single exam, its availability is
relatively low and is not well suited for use in those
with cardiac pacemakers, cardiac resynchronization
therapy devices, internal cardiac deﬁbrillators, or in-
tracranial metal. Moreover, in patients with renal
insufﬁciency (estimated glomerular ﬁltration rates
#30 ml/min), precaution is needed when gadolinium
contrast is considered because of an increased inci-
dence of nephrogenic systemic ﬁbrosis (92).
INVESTIGATIVE NONINVASIVE IMAGING
STRATEGIES FOR SCREENING CANCER
TREATMENT-RELATED CARDIOTOXICITY
In addition to current clinical applications, there are
additional initiatives underway in research venues to
image processes involved in cancer therapy-relatedent
xial plane at the level of the pulmonary artery and perpendicular to
ending thoracic aortas was obtained by tracing the centerline of the
thoracic aorta. The sagittal magnitude image demonstrates the
ansit time of the ﬂow wave was computed on the basis of the upstroke
line). The location of the best cross-correlation of 2 partial upstroke
(PWV) was calculated by dividing the distance between the ascending
rdiac magnetic resonance-derived aortic stiffness was determined
ancer (A) and participants who are receiving cancer therapy (B) at
in participants receiving anthracycline-based therapy. The magnitude
ffness age-associated increase of 15 years. Reprinted with permission
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831CV injury. These include molecular and metabolism-
targeted imaging. These forms of imaging charac-
terize biological processes at the cellular and
molecular level within living organisms, utilizing
injectable imaging agents or genetically encoded re-
porters. Although originating with targeted nuclear
imaging, there are now a variety of imaging agents
and modalities evolving as methods to detect car-
diotoxicity after treatment for cancer (88,93).
IMAGING OF APOPTOSIS AND CELL DEATH.
Apoptosis, the physiological adenosine triphosphate
(ATP)-dependent, noninﬂammatory process of pro-
grammed cell death resulting in fragmentation and
shrinkage of nuclear material, or myocyte death cul-
minates in the activation of a variety of proteins that
can serve as imaging biomarkers. Phosphatidylserine
(PS), one such protein, is expressed on the cell
membrane and serves as a noninvasive imaging
biomarker of apoptosis (88,93,94).
Annexin V—a high-afﬁnity calcium-depending PS-
binding protein conjugated to radioisotopes (such as
99mTc) in SPECT imaging, to magnetic iron oxide
nanoparticles and gadolinium-containing liposomes
in CMR, to positron emitters in PET, and to ﬂuores-
cence markers in optical imaging—has been used to
detect in vivo cell death that is due to myocardial
infarction, heart transplant rejection, and end-stage
LV dysfunction in human subjects, and cancer-
related therapy in animal models. In animal studies
of acute and chronic doxorubicin cardiac toxicity, a
signiﬁcant increase in 99mTc-Annexin V uptake in the
myocardium, with dose-dependent cell death con-
ﬁrmed by histopathology and immunohistochemistry,
was related to subsequent ventricular dysfunction
conﬁrmed by echocardiography (95–97). Recently,
Annexin V-based magnetoﬂuorescent suprapara-
magnetic iron oxide nanoparticles in combination
with T2*-weighted CMR revealed diffuse myocardial
T2* signal loss that correlated with increased caspase
activity in an animal receiving anthracyclines (98).
Another imaging-related biomarker of cellular
apoptosis relates to the activation of caspase pro-
teins. Activation of caspases is associated with
cellular apoptosis. In animals, a signiﬁcant increase
in caspase-3 activity has been observed within
LV myocardium after treatment with doxorubicin
(99,100).
INFLAMMATION IMAGING. Inﬂammatory injury to
cardiac myocytes disrupts the cellular membrane
promoting the release of a myosin heavy chain. In-
vestigators developed monoclonal antibodies, 111In
and 99mTc, to identify these heavy chains and thereby
assess the degree of myocyte damage in response toinﬂammation. Studies by Valdes Olmos et al. (101)
and Maini et al. (102) both show positive correlation
between the cumulative dose of anthracycline and
the uptake of antimyosin in the myocardium, with
later deterioration of LVEF (101,102) (Fig. 3). Impor-
tantly, however, the speciﬁcity of 111In-antimyosin
scintigraphy is low (25% to 50%) for predicting dec-
rements in LVEF 12 months after receipt of cancer
treatment (78).
MYOCARDIAL METABOLISM IMAGING. Magnetic
resonance spectroscopy (MRS) imaging can assess
multiple metabolic pathways simultaneously without
exposure to ionizing radiation. The principle of MRS
is that the chemical shift inﬂuences the different
resonance frequencies, allowing for the differentia-
tion of nuclei of the same species in different mole-
cules. MRS allows direct measurement of biochemical
information about in vivo processes involving phos-
phorous (31P), hydrogen (1H), carbon (13C), sodium
(23Na), nitrogen (15N), and ﬂuorine (19F). Currently,
only 31P has been studied in the assessment of
doxorubicin-related cardiotoxicity. In animals re-
ceiving doxorubicin, phosphocreatine to adenosine
triphosphate ratios (103) and phosphocreatine levels
(89) differed after stress compared with those not
receiving doxorubicin. These pre-clinical data suggest
that MRS may be able to detect abnormal mitochon-
drial ATP production/utilization related anthracy-
cline therapy.
Myocardial fatty acid metabolism assessed with
the SPECT radiotracers IPPA [15-(p-iodophenyl) pen-
tadecanoic acid] and BMIPP (123I-betamethyl-p-iodo-
phenyl pentadecanoic acid) have been measured in
subjects receiving anthracycline and other chemo-
therapeutic agents. A study by Saito et al. (104,105)
demonstrated early decreased uptake of 123I-BMIPP in
patients with preserved LV function after treatment
with an anthracycline; similar decreases in 123I-BMIPP
uptake were observed in patients experiencing a
decline in LVEF after receipt of a taxane and carbo-
platin. Recently, Carboni et al. (106) evaluated mito-
chondrial metabolism with 99mTc-sestamibi in
patients receiving multiagent chemotherapy. These
investigators demonstrated both early and delayed
cardiac 99mTc-sestamibi uptake with rapid washout
rates reﬂective of mitochondrial membrane dysfunc-
tion that were associated with an adverse cardiovas-
cular prognosis (106).
PET with its ability to quantify myocardial blood
ﬂow, oxygen extraction (using 15O as a tracer),
myocardial glucose metabolism, and fatty acid meta-
bolism has been preliminarily investigated regarding
the detection of cardiac toxicity after receipt of cancer
FIGURE 3 Sequential Antimyosin and MIBG Studies Before Chemotherapy
Sequential antimyosin (A, B, and C) and MIBG (A0, B0, and C0) studies before chemotherapy (A and A0) at 240 to 300 mg/m2 (B and B0) and at
420 to 600 mg/m2 (C and C0) of doxorubicin. There is a pattern of increasing myocardial antimyosin uptake with decreasing myocardial
metaiodobenzylguanidine (MIBG) uptake, both reﬂecting ongoing myocellular injury from anthracycline-based chemotherapy. Reprinted with
permission from Carrió et al. (28).
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832treatment. A recent study by Borde et al. (107)
demonstrated enhanced myocardial 18F-ﬂuorodeox-
yglucose (FDG) uptake in patients treated with
anthracyclines. In addition, Toubert et al. (108)
demonstrated decreased myocardial uptake of
18F-FDG in patients treated with a combination of
tyrosine kinase inhibitors (imatinib and sorafenib)
who later developed a cardiac event. It is important to
note that FDG uptake is nonspeciﬁc and its uptake can
change after other disease processes such as diabetes,
and thus, fasting status and pre-scan diet must be
considered when interpreting the study results.
ANGIOGENESIS IMAGING. Angiogenesis is generally
deﬁned as the development of new capillaries from
pre-existing microvessels. This complex multistep
process involves a variety of cells responding to both
stimulatory and inhibitory factors. Several conditions
stimulate the angiogenic process, including: ischemia,
hypoxia, inﬂammation, shear stress, and traumatic
injury (109). Tumors also modify angiogenesis to
enhance their blood supply. For this reason, therapy
directed to prevent tumor-associated angiogenesis
(“antiangiogenesis therapy”) has become one of
the cornerstones of many modern chemothera-
peutic regimens (109). To assess the efﬁcacy ofantiangiogenesis therapy, angiogenesis imaging has
been developed utilizing: 1) non-endothelial cell tar-
gets (molecules associated with monocytes, macro-
phages, and stem cells); 2) endothelial cell targets
(vascular endothelial growth factor [VEGF], integrins,
CD13, and syndecan-4); and 3) extracellular matrix
proteins (94,109,110).
Although antiangiogenesis therapy has been found
useful for treating cancer, it is now recognized that
adverse microcirculatory effects (e.g., hypertension,
organ dysfunction) of non–tumor-related host organ
tissues occurs after administration of these agents
(110). Currently, studies have relied on clinical end-
points to identify and determine the functional
importance of injury related to these agents. In ani-
mals, investigators have explored the use of isotopes
or paramagnetic traces linked directly to VEGF re-
ceptors and integrin avb3 to directly monitor pro-
gression of angiogenesis within CV tissues exposed to
antiangiogenic cancer therapy (94,109,110).
DIRECT IMAGING OF CHEMOTHERAPEUTICS AGENTS.
Directly imaging of chemotherapeutic agents is also
an area of active research. Thus far, however, results
have been somewhat contradictory. For example,
Behr et al. (111) observed reduced uptake of
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833111In-labeled trastuzumab in the myocardium of
patients who developed heart failure and arrhythmia,
whereas Perik et al. (112) noticed no myocardial up-
take in patients who developed severe symptomatic
LV dysfunction during treatment with trastuzumab
(111,112). Directly imaging the effects of these agents
may also depend on the timing of the image acquisi-
tion relative to the administration of the cancer
treatment. For example, de Korte et al. (113) identiﬁed
that myocardial HER2 overexpression was up-
regulated by cardiac stress induced by the anthracy-
cline administration, but was not present in patients
receiving non–anthracycline-based regimens months
after receiving their treatment.
CURRENT RECOMMENDATIONS
IN CV IMAGING
To date, few, if any, guideline statements exist
regarding the implementation of noninvasive imag-
ing techniques for the purpose of monitoring patients
receiving treatment for cancer. There has, however,
been several suggested management algorithms
published over the last 10 years. To date, these
algorithms have been created for assessment
of those receiving radiation, anthracyclines, or
trastuzumab.
In regard to assessments of patients receiving
radiation therapy, the European Association of Car-
diovascular Imaging and the American Society of
Echocardiography recently published an expert
consensus statement for multimodality imaging
evaluation of cardiovascular complications of radio-
therapy in adults (114). This document encompasses
assessments of LV function, pericardial diseases, and
valvular heart disease. Also, in the case of breast
cancer, the document addresses issues associated
with irradiation of the right and left breasts.
In regard to receipt of anthracycline-based
chemotherapy, there are no evidence-based guide-
lines for CV monitoring during therapy. The only
established guidelines for CV monitoring in chil-
dren during treatment were published in 1992, by
Steinherz et al. (23). This report of the Cardiology
Committee of the Children’s Cancer Study Group
suggested an algorithm for the use of echocardio-
grams or nuclear medicine scans for assessing chil-
dren scheduled to receive anthracycline-based
chemotherapy (50). This particular statement does
not address newer methodologies available (bio-
markers, advanced imaging with echocardiography
or CMR) that may provide evidence of early cardiac
or vascular injury before a decline in LVEF or frac-
tional shortening. More recently, the CardiologyCommittee of the Children’s Cancer Study Group (23)
and Lipshultz et al. (115) indicated that echocardiog-
raphy with its widespread availability and CMR, when
echocardiography is not suitable, could be utilized to
identify CV injury upon receipt of chemotherapy in
children.
For adults, the European Society for Medical
Oncology provided recommendations for assessment
of adult patients scheduled to receive anthracycline-
based chemotherapy (116). Similar to the recommen-
dations produced in 1992 for children, the current
suggestions for assessment of anthracyclines in
adults remain primarily based on radioisotope,
echocardiographic, or CMR assessments of LVEF. As
with assessments in children, these recommenda-
tions do not incorporate assessments of subclinical
CVD that may portend the future occurrence of
advanced CV events. Moreover, these suggestions
are developed to prevent the occurrence of marked
deteriorations in LVEF. Following either of the chil-
dren or adult recommendations for monitoring LVEF
upon receipt of anthracycline-based chemotherapy
does not guarantee the absence of any future CV
events should individuals survive their cancer
treatment.
Raschi et al. (117) published algorithms for moni-
toring LVEF upon receipt of trastuzumab (Hercep-
tin). Unlike the recommendations pertaining to the
administration of anthracyclines, the suggestions
provided by Raschi et al. do incorporate measure-
ments of serum biomarkers such as troponin and B-
type natriuretic peptide. In addition, suggestions
for restarting trastuzumab in the setting of patients
that recover their LVEF are provided. However, as
with the suggestions to date regarding the adminis-
tration of radiation therapy and anthracyclines to
children or adults, these current recommendations for
trastuzumab do not address the development of sub-
clinical CV injury nor protection against the late
occurrence of CV events in cancer survivors. Similar to
the suggestions provided for radiation treatment
and anthracyclines, the suggestions for assessments
of patients receiving trastuzumab are directed pri-
marily at preventing relatively large declines in
LVEF.
SUMMARY AND FUTURE DIRECTIONS
As shown in Figure 4, there are multiple potential
sites and pathways that can be affected by the
administration of chemotherapy, and multiple pos-
sibilities for clinical (radionuclide, transthoracic
echocardiographic, and magnetic resonance) and
research developmental (targeted molecular imaging)
FIGURE 4 Imaging Techniques in Clinical Use and in Development
Opportunities for utilizing existing (black boxes) and developmental (red boxes) noninvasive imaging technologies for identifying processes associated with myocellular,
myoﬁbroblast, myocardial conduction, and vascular injuries associated with the administration of cancer therapies that may adversely impact the cardiovascular (CV)
system. As shown, existing technologies identify mainly clinically evident manifestations of CV injury, whereas developmental technologies may facilitate assessment of
biomolecular pathways that precede end-organ damage. Ab¼ antibody; CT¼ computed tomography; ERNA¼ equilibrium radionuclide angiography; LV¼ left ventricular;
MRI ¼ magnetic resonance imaging; MRA ¼ magnetic resonance angiography; MUGA ¼ multigated acquisition scanning; PET ¼ positron emission tomography.
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834methods that may enable detection of the CV effects
of cancer treatment.
What then should be the current areas of focus for
research in CV imaging as it pertains to the ﬁeld of
cardio-oncology? First, to date, the majority of the
management algorithms have focused on the primary
use of noninvasive imaging to assess LVEF. Although
LVEF is important, it may not reﬂect the underlying
advancements of subclinical CVD that could portend
the development of CV events in patients actively
treated for or those that survive cancer. Imaging
research is necessary to understand the entirety of CV
effects after treatment for cancer. This research needs
to address therapies beyond the administration of
anthracyclines, as shown in Online Table 1.Second, the array of current and future imaging
metrics (Fig. 4) need to be evaluated in terms of pre-
dicting future CV events in patients treated for cancer.
These imaging-related measures need to be evaluated
in the context of existing risk factor prediction models
for forecasting risk. Are these imaging markers bene-
ﬁcial and reliable? In which of the patients receiving
speciﬁc subsets of cancer therapies should the imag-
ing markers be applied? In addition, when should they
be utilized, and what are the economic consequences
of their use?
Third, does CV imaging have a role in guiding
therapy to prevent CV injury after treatment for
cancer? If so, how and when should this imaging be
implemented, to what extent, and by whom? To date,
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835CV imaging studies are interpreted primarily by MD or
DO physicians with advanced imaging training. Can
surveillance imaging programs be designed that uti-
lize this high physician level of expertise in a super-
visory rather than a direct interpretive role?
In summary, new advancements related to the
treatment of cancer have improved cancer-related
survival, but, in many cases, have also increased the
risk of CV injury and CV events. To date, noninvasive
imaging has been used to assess LVEF before initia-
tion of cancer treatment and in those who develop
symptoms after treatment commences. Ongoing and
future investigations will help determine the suit-
ability of noninvasive imaging modalities to identifythose at risk of developing CV injury upon receipt of
cancer treatment and whether noninvasive imaging
can be utilized to guide the administration of addi-
tional protective therapies to prevent CV injury and
events after treatment for cancer. Preventing CV
events in patients treated for cancer provides an op-
portunity to improve overall cancer survivorship and
quality of life.
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